ACVR2A
ACVR2A encodes a receptor involved in TGF-beta signaling and cellular growth regulation. Alterations in ACVR2A have been associated with certain gastrointestinal cancers and may inform targeted or investigational therapy strategies.
Where this biomarker is used
Each approval combines this biomarker with a specific indication and therapy. Select a therapy in the tables below to open its FDA-defined testing pathway.
Approvals where ACVR2A is defined directly in the indication labeling.
| Indication | Biomarker criteria | Therapies |
|---|---|---|
Colorectal Cancer (CRC) Solid Tumor · Colorectal |
|
Approvals defined at the solid tumor level where ACVR2A is part of the eligibility criteria.
No tumor-agnostic approvals are currently mapped for this biomarker.
Tests that measure this biomarker
These assays report ACVR2A as part of their validated menu. In many cases they are identified in FDA labeling as acceptable companion diagnostics for specific approvals.
Reports ACVR2A as part of its biomarker panel.